Intellia Therapeutics (NTLA) Other Non-Current Liabilities (2015 - 2022)
Intellia Therapeutics (NTLA) posted quarterly Other Non-Current Liabilities of $24.0 million for Q4 2022, up 29.17% quarter-over-quarter from $18.6 million in Q3 2022.
Powered by 
Analysis
Intellia Therapeutics (NTLA) Other Non-Current Liabilities (2015 - 2022) Analysis & Trends
Intellia Therapeutics (NTLA) has reported Other Non-Current Liabilities for 5 consecutive years, with $24.0 million the latest figure, recorded in Q4 2022.
- In Q4 2022, Other Non-Current Liabilities changed N/A year-over-year to $24.0 million; the TTM figure through Dec 2022 stood at $24.0 million (changed N/A YoY), while the FY2022 annual figure was $24.0 million, changed N/A from the prior year.
- Other Non-Current Liabilities grew to $24.0 million in Q4 2022 per NTLA's latest filing, from $18.6 million in the prior quarter.
- Across five years, Other Non-Current Liabilities topped out at $24.0 million in Q4 2022 and bottomed at $13000.0 in Q4 2018.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn |
| 10 | Intellia Therapeutics | 1.70 Bn | 1.70 Bn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Dec 31, 2022 | 24.03 Mn |
| Sep 30, 2022 | 18.60 Mn |
| Jun 30, 2022 | 10.79 Mn |
| Mar 31, 2022 | 10.96 Mn |
| Dec 31, 2018 | 13,000.00 |
| Sep 30, 2018 | 52,000.00 |
| Jun 30, 2018 | 92,000.00 |
| Mar 31, 2018 | 131,000.00 |
| Dec 31, 2017 | 168,000.00 |
| Sep 30, 2017 | 201,000.00 |
| Jun 30, 2017 | 234,000.00 |
| Mar 31, 2017 | 378,000.00 |
| Dec 31, 2016 | 293,000.00 |
| Sep 30, 2016 | 306,000.00 |
| Jun 30, 2016 | 363,000.00 |
| Mar 31, 2016 | 349,000.00 |
| Dec 31, 2015 | 323,000.00 |